The global collateral ligament stabilizer system market is expected to reach USD 2.36 billion by 2025,
according to a new report by Grand View Research, Inc. Increase in number of
sports injuries and road accidents is expected to boost the adoption of
Collateral Ligament Stabilizer System (CLSS). According to Stanford Children’s
Health, around 3.5 million children aged 14 years and below are affected by
some form of sport-related injury every year. This shows the potential demand
for CLSS in the coming years.
Nearly one-third of all injuries affecting
children arise due to sport-related activities. Sports Medicine Australia also
estimated that 1 in 17 Australians suffer from sport trauma each year.
According to the Zurich American Insurance Company, 62% of the injuries related
to organized sports occur during practices. Thus, increasing sports-related
injuries has resulted in the high demand for collateral ligament stabilizer
systems.
According to WHO, every year nearly 1.25
million people die due to road accidents and about 20 to 50 million are
injured. Thus, the rise in number of road accidents is anticipated to heighten
the adoption of CLSS.
Furthermore, increasing geriatric
population across the globe is another major factor propelling the growth of
CLSS market. According to a report published by the U.S. Census Bureau, Japan
has the highest percentage of aging population in the world. In 2015, about
26.6% of the population in Japan was aged 65 years and over, which accounted
for nearly 33.7 million people.
Browse full report by Grand View
Research :
http://www.grandviewresearch.com/industry-analysis/collateral-ligament-stabilizer-system-market
http://www.grandviewresearch.com/industry-analysis/collateral-ligament-stabilizer-system-market
Further Key Findings From the Study Suggest:
·
The medial collateral ligament segment held
the dominant share owing to the increase in number of medial collateral
ligament trauma resulting from sports or road accidents
·
The grade 2 injury segment is anticipated
to grow at a lucrative CAGR due to the increase in number of grade 2 injuries
and recommendations by medical practitioners to use collateral ligament
stabilizer systems in such cases
·
On the basis of end use, orthopedic clinics
held the largest share of the CLSS market owing to the increase in
establishment of specialty clinics and growing preference of patients for such
clinics
·
Asia Pacific is anticipated to grow at a
lucrative CAGR owing to presence of high untapped opportunities, rising prevalence
of chronic conditions such as osteoarthritis, and rise in number of accident
& trauma cases
Browse more reports of this category by Grand View
Research: https://www.grandviewresearch.com/industry/medical-devices
Grand View Research has segmented the
Collateral Ligament Stabilizer System (CLSS) market on the basis of ligament,
injury, end use, and region:
Collateral Ligament Stabilizer System Ligament Outlook
(Revenue, USD Million, 2014 - 2025)
·
Medial Collateral Ligament (MCL)
·
Lateral Collateral Ligament (LCL)
Collateral Ligament Stabilizer System Injury Type Outlook
(Revenue, USD Million, 2014 - 2025)
·
Grade 1
·
Grade 2
·
Grade 3
Collateral Ligament Stabilizer System End-use Outlook (Revenue,
USD Million, 2014 - 2025)
·
Hospitals
·
Orthopedic Clinics
·
Others
Collateral Ligament Stabilizer System Regional Outlook
(Revenue, USD Million, 2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o UK
o Germany
·
Asia Pacific
o Japan
o China
o India
·
Latin America
o Brazil
o Mexico
·
MEA
o South Africa
Access press release by
Grand View Research:
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment